Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.